348 related articles for article (PubMed ID: 21423750)
1. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.
Roychoudhury J; Sinha R; Ali N
PLoS One; 2011 Mar; 6(3):e17376. PubMed ID: 21423750
[TBL] [Abstract][Full Text] [Related]
2. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
Sinha R; Roychoudhury J; Palit P; Ali N
Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
[TBL] [Abstract][Full Text] [Related]
3. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
Joshi J; Kaur S
Parasitology; 2014 Apr; 141(4):554-62. PubMed ID: 24618257
[TBL] [Abstract][Full Text] [Related]
4. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
Banduwardene R; Mullen AB; Carter KC
Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
[TBL] [Abstract][Full Text] [Related]
5. Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase.
Carter KC; Hutchison S; Henriquez FL; Légaré D; Ouellette M; Roberts CW; Mullen AB
Antimicrob Agents Chemother; 2006 Jan; 50(1):88-95. PubMed ID: 16377672
[TBL] [Abstract][Full Text] [Related]
6. Activity of rutin, a potent flavonoid against SSG-sensitive and -resistant Leishmania donovani parasites in experimental leishmaniasis.
Chauhan K; Kaur G; Kaur S
Int Immunopharmacol; 2018 Nov; 64():372-385. PubMed ID: 30245348
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.
Pal S; Ravindran R; Ali N
Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135
[TBL] [Abstract][Full Text] [Related]
8. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
Banerjee A; De M; Ali N
J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
[TBL] [Abstract][Full Text] [Related]
9. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Dube A; Singh N; Sundar S; Singh N
Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
[TBL] [Abstract][Full Text] [Related]
10. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.
Carter KC; Baillie AJ; Mullen AB
Clin Diagn Lab Immunol; 1999 Jan; 6(1):61-5. PubMed ID: 9874665
[TBL] [Abstract][Full Text] [Related]
11. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
Carter KC; Mullen AB; Sundar S; Kenney RT
Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
[TBL] [Abstract][Full Text] [Related]
12. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.
Carter KC; Hutchison S; Boitelle A; Murray HW; Sundar S; Mullen AB
Parasitology; 2005 Dec; 131(Pt 6):747-57. PubMed ID: 16336728
[TBL] [Abstract][Full Text] [Related]
13. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
Carter KC; Sundar S; Spickett C; Pereira OC; Mullen AB
Antimicrob Agents Chemother; 2003 May; 47(5):1529-35. PubMed ID: 12709318
[TBL] [Abstract][Full Text] [Related]
14. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
Mullen AB; Lawrence CE; McFarlane E; Wei XQ; Carter KC
Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
[TBL] [Abstract][Full Text] [Related]
15. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.
Banerjee A; De M; Ali N
Antimicrob Agents Chemother; 2011 Apr; 55(4):1661-70. PubMed ID: 21220536
[TBL] [Abstract][Full Text] [Related]
17. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
[TBL] [Abstract][Full Text] [Related]
18. Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.
Vanaerschot M; De Doncker S; Rijal S; Maes L; Dujardin JC; Decuypere S
PLoS One; 2011; 6(8):e23120. PubMed ID: 21829701
[TBL] [Abstract][Full Text] [Related]
19. Genetic control of drug-induced recovery from murine visceral leishmaniasis.
Carter KC; Baillie AJ; Alexander J
J Pharm Pharmacol; 1993 Sep; 45(9):795-8. PubMed ID: 7903366
[TBL] [Abstract][Full Text] [Related]
20. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
